Inactivated MG Bac Vaccine

Respiratory mycoplasmosis in poultry, caused by Mycoplasma gallisepticum, poses a serious threat to poultry farms, leading to chronic respiratory disease, reduced egg production, and poor feed conversion. To reliably protect flocks from this infection, Zoetis developed the inactivated emulsion vaccine MG Bac. The vaccine is based on a culture of M. gallisepticum (strain R-980), inactivated with formaldehyde, ensuring the highest level of safety without the risk of spreading live pathogens.

The main advantage of MG Bac for commercial and breeding poultry farms is its extremely low reactogenicity, allowing safe vaccination even for young chicks. The vaccine induces a strong and uniform immune response, which is fully developed 4 weeks after two administrations and provides reliable protection throughout the productive period. Its injectable emulsion form ensures absolute dosing accuracy for each bird.

Implementing MG Bac in your farm’s biosecurity program is an effective tool for complete control of respiratory mycoplasmosis. A protected flock demonstrates maximum productivity, high hatchability of healthy chicks, and optimal feed utilization. This is a strategic investment in biosecurity, significantly reducing antibacterial therapy costs and ensuring stable high profitability for your business.